(Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 10.19%101.2B | 1.94%48.27B | -55.14%175.45B | -57.49%134.56B | -56.43%91.84B | -55.13%47.35B | 17.19%391.06B | 36.75%316.55B | 51.36%210.79B | 62.75%105.53B |
Operating income | 10.19%101.2B | 1.94%48.27B | -55.14%175.45B | -57.49%134.56B | -56.43%91.84B | -55.13%47.35B | 17.19%391.06B | 36.75%316.55B | 51.36%210.79B | 62.75%105.53B |
Cost of sales | -8.30%-78.04B | ---- | 32.97%-147.86B | ---- | 36.09%-72.06B | ---- | -13.95%-220.58B | ---- | -30.90%-112.75B | ---- |
Operating expenses | -8.30%-78.04B | -5.76%-38.91B | 32.97%-147.86B | 36.54%-108.97B | 36.09%-72.06B | 41.37%-36.79B | -13.95%-220.58B | -31.85%-171.71B | -30.90%-112.75B | -44.90%-62.75B |
Gross profit | 17.07%23.16B | -11.39%9.36B | -83.82%27.59B | -82.34%25.58B | -79.82%19.78B | -75.31%10.56B | 21.67%170.48B | 43.06%144.85B | 84.54%98.04B | 98.65%42.78B |
Selling expenses | -11.94%-4.57B | -1,436.70%-232.81M | 30.22%-8.23B | -2,039.55%-823.64M | 37.35%-4.09B | -30.34%-15.15M | 4.31%-11.8B | 15.26%-38.5M | -17.15%-6.52B | 13.49%-11.62M |
Administrative expenses | ---- | 25.37%-1.69B | ---- | 44.61%-4.59B | ---- | 14.82%-2.27B | ---- | -8.31%-8.29B | ---- | -9.17%-2.67B |
Research and development expenses | ---- | -22.29%-256.54M | ---- | 23.62%-757.18M | ---- | -28.89%-209.78M | ---- | -47.22%-991.31M | ---- | -284.36%-162.76M |
Profit from asset sales | ---- | 478.20%39.85M | ---- | -75.02%83.43M | ---- | -96.38%6.89M | ---- | 85.26%334.03M | ---- | 1,067.82%190.5M |
Revaluation surplus | ---- | -65.67%6.52M | ---- | 148.49%33.55M | ---- | 138.47%18.98M | ---- | -254.62%-69.2M | ---- | -1,586.74%-49.34M |
-Changes in the fair value of other assets | ---- | -65.67%6.52M | ---- | 148.49%33.55M | ---- | 138.47%18.98M | ---- | -254.62%-69.2M | ---- | -1,586.74%-49.34M |
Impairment and provision | -145.57%-82.79M | -25.03%-48.37M | 730.36%225.16M | 140.79%212.42M | 140.44%181.67M | 58.18%-38.68M | 80.28%-35.72M | -283.01%-520.75M | -614.40%-449.26M | -493.00%-92.51M |
-Other impairment is provision | -145.57%-82.79M | -25.03%-48.37M | 730.36%225.16M | 140.79%212.42M | 140.44%181.67M | 58.18%-38.68M | 80.28%-35.72M | -283.01%-520.75M | -614.40%-449.26M | -493.00%-92.51M |
Special items of operating profit | -75.54%551.29M | 7.43%1.35B | 16.25%5.06B | 115.38%6.6B | 153.83%2.25B | 70.03%1.26B | 490.84%4.35B | 28.43%3.07B | 56.87%887.85M | -1.81%739.6M |
Operating profit | 5.09%19.05B | -8.46%8.25B | -84.88%24.64B | -81.29%25.5B | -80.28%18.13B | -77.49%9.01B | 27.00%163B | 43.21%136.26B | 91.32%91.96B | 102.82%40.04B |
Financing income | -26.03%3.09B | ---- | 30.99%7.47B | ---- | 85.26%4.18B | ---- | 413.89%5.71B | ---- | 601.28%2.26B | ---- |
Financing cost | 8.88%-1.66B | 8.26%909.12M | 2.74%-3.74B | 6.44%5.08B | 0.35%-1.83B | 333.19%839.72M | -0.19%-3.84B | 331.49%4.77B | 3.62%-1.83B | 56.52%-360.1M |
Share of profits of associates | 6.66%2.29B | ---- | 146.19%4.09B | ---- | 155.50%2.15B | ---- | -1.58%1.66B | ---- | -8.19%839.55M | ---- |
Share of profit from joint venture company | -3.88%294.36M | ---- | -6.77%606.01M | ---- | -8.66%306.24M | ---- | -6.40%650.02M | ---- | -9.69%335.28M | ---- |
Special items of earning before tax | ---- | -145.50%-1.46M | ---- | 80.41%-24.58M | ---- | 169.94%3.21M | ---- | -853.64%-125.51M | ---- | -85.04%1.19M |
Earning before tax | 0.56%23.06B | -7.08%9.16B | -80.21%33.08B | -78.32%30.55B | -75.49%22.93B | -75.16%9.86B | 30.60%167.18B | 51.40%140.91B | 95.85%93.55B | 109.72%39.68B |
Tax | -16.82%-3.8B | -15.86%-1.48B | 86.87%-4.68B | 82.15%-4.55B | 80.58%-3.26B | 82.08%-1.27B | -47.87%-35.64B | -69.88%-25.49B | -242.35%-16.77B | -532.82%-7.11B |
After-tax profit from continuing operations | -2.14%19.26B | -10.49%7.68B | -78.41%28.4B | -77.47%26B | -74.38%19.68B | -73.65%8.58B | 26.59%131.54B | 47.85%115.41B | 79.11%76.78B | 83.00%32.57B |
Earning after tax | -2.14%19.26B | -10.49%7.68B | -78.41%28.4B | -77.47%26B | -74.38%19.68B | -73.65%8.58B | 26.59%131.54B | 47.85%115.41B | 79.11%76.78B | 83.00%32.57B |
Minority profit | -23.43%2.39B | -36.26%927.11M | -79.14%4.54B | -78.23%3.93B | -73.96%3.12B | -70.55%1.45B | 49.38%21.74B | 72.91%18.04B | 107.26%11.96B | 110.70%4.94B |
Profit attributable to shareholders | 1.87%16.87B | -5.23%6.76B | -78.27%23.86B | -77.33%22.07B | -74.45%16.56B | -74.20%7.13B | 22.88%109.79B | 43.98%97.38B | 74.73%64.82B | 78.80%27.63B |
Basic earnings per share | 1.94%1.05 | -4.55%0.42 | -78.36%1.48 | -77.43%1.37 | -74.57%1.03 | -74.57%0.44 | 22.36%6.84 | 43.16%6.07 | 73.82%4.05 | 78.35%1.73 |
Diluted earnings per share | 2.94%1.05 | -4.55%0.42 | -78.20%1.48 | -77.52%1.36 | -74.69%1.02 | -74.42%0.44 | 22.12%6.79 | 43.03%6.05 | 73.71%4.03 | 79.17%1.72 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Auditor | -- | -- | Shinnaganaka & Chung Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shinnaganaka & Chung Certified Public Accountants (Special General Partnership) | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data